Related Experiment Video
Updated: Dec 31, 2025
07:39
Use of a Percutaneous Ventricular Assist Device/Left Atrium to Femoral Artery Bypass System for Cardiogenic Shock
Published on: August 16, 2021
4.0K
Impact of renal function recovery utilizing left ventricular assist device support
Mohammed Quader1, Adam M Goodreau1, Ryan M Johnson1
1Department of Surgery, Division of Cardio-thoracic Surgery, Virginia Commonwealth University, Richmond, Virginia.
Journal of Cardiac Surgery
|January 4, 2020
Summary
Left ventricular assist device (LVAD) support significantly improves renal function in heart failure patients with renal insufficiency. Most patients requiring hemodialysis (HD) pre- or post-surgery recovered kidney function.
Area of Science:
- Cardiology
- Nephrology
- Medical Devices
Background:
- Heart failure (HF) patients often experience renal insufficiency (RI).
- Mechanical circulatory support (MCS) with left ventricular assist devices (LVADs) may impact renal recovery (RR).
Purpose of the Study:
- To quantify renal function recovery (RR) in HF patients with RI undergoing LVAD implantation.
- To assess RR over a 6-month follow-up period.
Main Methods:
- Analysis of RR data at 30, 90, and 180 days post-LVAD surgery.
- RI defined as hemodialysis (HD) use or glomerular filtration rate (GFR) < 60 mL/min/1.73 m².
- Included 47 of 127 (37%) LVAD recipients with preoperative RI.
Main Results:
- Mean preoperative GFR was 48 ± 7 mL/min/1.73 m².
- Significant GFR improvements observed at 30, 90, and 180 days (P < .001).
- Majority of patients requiring pre- or post-operative HD recovered renal function.
Conclusions:
- LVAD support leads to significant improvement in renal insufficiency.
- GFR increases are most pronounced within the first 30 days post-implantation.
- LVAD therapy is a viable option for improving renal function in HF patients with RI.
More Related Videos
Related Concept Videos
01:22Heart Failure VI: Adjunct Therapies
207
Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
207
01:29Cardiomyopathy V: Interprofessional Care
260
Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
260
01:29Acute Kidney Injury III: Clinical Manifestations
709
Acute Kidney Injury (AKI) progresses through distinct clinical phases: the oliguric, diuretic, and recovery phases, each marked by unique manifestations and challenges.Oliguric Phase:The oliguric phase is the initial stage of AKI, typically lasting 10 to 14 days. This phase is marked by a significant reduction in urine output, usually less than 400 mL per day, indicating decreased kidney function. Fluid retention is a prominent feature, leading to symptoms such as edema, hypertension, and...
709
01:22Heart Failure Drugs: Diuretics
751
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
751
01:30Continuous Renal Replacement Therapy
647
Continuous Renal Replacement Therapy, also known as CRRT, is a procedural treatment for acute kidney injury (AKI) that gradually removes uremic toxins and fluids while maintaining acid-base balance and stabilizing electrolytes. It is particularly useful for hemodynamically unstable patients. Unlike intermittent hemodialysis, which is faster, CRRT provides a gentler approach over 24 hours, closely mimicking the function of natural kidneys. However, CRRT is not ideal for patients with...
647
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
846
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
846